Abstract:Herein, we review interventional peripheral neuromodulatory approaches to reduce blood pressure (BP), specifically focusing on catheter-based renal denervation (RDN), as well as the latest data from recent clinical trials underpinning its clinical use. Given the apparent failure of established lifestyle measures and pharmacologic BP-lowering approaches to improve hypertension (HTN) control rates, the past decade has seen remarkable scientific efforts to explore the utility of interventional strategies for BP management. Experimental studies and human clinical trials have demonstrated the crucial role of the sympathetic nervous system in the development and mainenance of HTN - consequently, most recent interventional technologies aimed primarily at modulating neural pathways. Advanced approaches that were rigorously tested in human studies include RDN, endovascular baroreflex amplification, baroreflex activation therapy and cardiac neuromodulation stimulation.Amongst these, RDN is by far the most established technology. With recent robust evidence from clinical trials and real-world data showing the safety and efficacy of both ultrasound and radiofrequency-based approaches, a recent clinical consensus statement of the European Society of Cardiology Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions concludes that RDN represents an ancillary therapeutic option in patients with uncontrolled resistant HTN confirmed by ambulatory blood pressure measurement and in spite of attention to lifestyle changes and optimised pharmacological treatment. Furthermore, RDN could alos be considered for patienst unlikley to adhere to or tolerate long-term antihypertensive drug treatment. Very recent data indicate long-term safety and efficacy up to 10 years. Appropriate implementation of RDN into clinical practice is now warranted.For all other interventions additional data from adequately designed human studies are required to establish their safety and clinical utility for potential future use in routine practice.

Innovative hypertension treatments: transitioning from conventional therapies to siRNA-based solutions

Emerging RNAi Therapies to Treat Hypertension

siRNA as potential therapeutic strategy for hypertension

Gene editing of angiotensin for blood pressure management

Taming resistant hypertension: The promise of novel pharmacologic approaches and renal denervation

Interventional procedures and future drug therapy for hypertension

Update on advanced interventional neuromodulatory approaches to lower blood pressure

siRNA therapeutics: insights, challenges, remedies and future prospects

Renal Denervation in the Management of Resistant Hypertension: A Comprehensive Review of Literature

New therapeutic targets in hypertension

RNA interference therapy in cardiology: will new targets improve therapeutic goals?

Present and future of drug therapy in hypertension: an overview

New Molecules for Treating Resistant Hypertension: a Clinical Perspective

Therapeutic siRNA: State-of-the-Art and Future Perspectives

Systematic Review Article: New Drug Strategies for Treating Resistant Hypertension-the Importance of a Mechanistic, Personalized Approach

The Increasing Problem of Resistant Hypertension: We'll Manage till Help Comes!

New and developing pharmacotherapies for hypertension

New Developments in the Pharmacological Treatment of Hypertension: Dead-End or a Glimmer at the Horizon?

Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure

[Resistant hypertension: integrated strategies between pharmacological treatment and renal denervation]

The role of selective imidazoline receptor agonists in modern hypertension management: an international real-world survey (STRAIGHT)